COLL vs EMBC: fair value comparison
Collegium Pharmaceutical, Inc. and Embecta Corp. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, COLL currently sits closer to the top of our ranking by discount to fair value.
| COLL | EMBC | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $23.19 | $6.27 |
| 12-month range | $21.53–$49.84 | $2.90–$14.64 |
| Rank by discount to fair value | #6 of 108 Healthcare | #11 of 108 Healthcare |
| Quality grade | B | B |
| Leverage | High | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | Strong | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Downtrend |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: COLL fair value analysis · EMBC fair value analysis